- Sandoz of Switzerland has licensed exclusive worldwide marketing rights to GraftSkin, a manufactured human skin product, from Organogenesis of the USA. A premarket approval application for GraftSkin in the treatment of venous stasis ulcers is currently under expedited review by the US Food and Drug Administration. Under the terms of the agreement, Sandoz will make up to $37.5 million in payments to Organogenesis in equity investments, milestone payments and research support.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze